SKYE Stock — Skye Bioscience Inc.: Cash, EV, Pipeline

Share price

$1.76

Market cap

$7.8M

Cash

$10.1M

Enterprise value

-$2.3M

Balance sheet

Cash	$10.1M
Debt	$0.0M
Net cash	$10.1M
Enterprise value	-$2.3M
Basic shares	35.1M shares
Fully diluted shares	36.8M shares
Fully diluted market cap	$64.8M
Cash per share	$0.29

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading SKYE daily closes…

Loading price history…

Pipeline assets

Nimacimab

Phase 2 · Terminated Modality: peripherally restricted negative allosteric modulating antibody (subcutaneous)

Target Cannabinoid receptor 1 (CB1)

Partnerships n/a (Halozyme ENHANZE license: termination notice sent August 11, 2026)

Indications

Obesity and overweight (Phase 2)

Status note CBeyond Phase 2a completed; an IV expansion study (Part C) was initiated in March 2026. In Q2 2026 management terminated the CBeyond trial and paused all associated R&D activities for nimacimab; company is pursuing the proposed acquisition of Redx Pharma (agreement signed August 14, 2026).

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Nimacimab injection
Lead indication	Obesity
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06577090	Phase 2	Active, not recruiting	Sponsor	SKYE	—	Obesity	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Skye Bioscience, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	1,575,243	no change	0.01%	2026-08-14
Sphera Biotech	678,928	no change	0.07%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

SKYE — Skye Bioscience Inc.